Painful Bladder Syndrome Clinical Trial
Official title:
Clinical Features and Histologic Findings in Bladder Pain Syndrome/Interstitial Cystitis (BPS/IS): New Findings on Useful Correlations
Objectives- to find out whether a correlation exists between denudation of urothelium and
diagnosic delay in patients with BPS / IC, secondary aim was to search a correlation between
impact of symptoms evaluated with ICSI-ICPI and number of comorbid conditions associated
with BPS-IC.
Patients and Methods- Fifty-seven consecutive patients underwent cystoscopy under
anaesthesia to classify those cases suspected of BPS/IC. As for the evaluation of the
ICSI-ICPI scores we considered significant relevant values those ≥ 12. Patients underwent
cystoscopy with hydrodistension under general (90%) or locoregional anaesthesia. Bladder
biopsies were taken, including detrusor muscle, from those areas with the most apparent
bladder wall lesions. All biopsies were then fixed in 4% formalin and sent to the
Pathologist for examination.
Between 2005 and 2016, in our Department 57 consecutive patients underwent cystoscopy under
anaesthesia to classify those cases suspected of BPS/IC. Patients reported long-lasting
irritative bladder symptoms, including urgency, daytime frequency of seven or more episodes,
nocturia, and pain in the lower abdomen, lower back, vagina or perineum during filling or
after micturition. Alternative diagnoses such as urinary tract infection (UTI) were
excluded. Confusable diseases were ruled out by thorough history, clinical examination,
urine analysis and imaging.
By means of a detailed medical history we considered the time of symptom onset, frequency of
micturitions, the presence of associated diseases. All patients were given the same
questionnaire (O'Leary-Sant Interstitial Cystitis Symptom and Problem Index) (19), filled at
the time of bladder biopsy.
As for the evaluation of the ICSI-ICPI scores we considered significant relevant values
those ≥ 12.
All patients underwent cystoscopy with hydrodistension under general (90%) or locoregional
anaesthesia. A rigid cystoscope with a Ch. 22 caliber was used, mannitol solution was used
as filling fluid, and infusion height was 80 cm above the symphysis pubis. During filling
the bladder was continuously inspected. At maximal capacity, distension was maintained until
spontaneous filling stopped and maximum capacity was reached. At this point the bladder was
drained and bladder walls and mucosa were closely examined . The bladder was then filled
again at approximately half capacity, and at least three deep biopsies were taken, including
detrusor muscle, from those areas with the most apparent bladder wall lesions.
All biopsies were then fixed in 4% formalin and sent to the Pathologist for examination. It
was specifically asked to assess the presence of urothelial denudation, inflammatory
infiltrate, counts of mast cells in the submucosa and detrusor, presence of intrafascicular
fibrosis and submucosal bleeding. A cut-off of 28 mast cells / mm2 was used for the
assessment of detrusor mastocytosis.
Morphologic Study Biopsy samples were cut in 5-μm-thick sections, then stained with the
following reagents for morphologic evaluation: Hematoxylin-Eosin, Giemsa and Masson
Tricromic Stain. This procedure was performed by automatic stainers (Leica, mod. ST5020 and
mod. Autostainer™ XL).
In each biopsy the following parameters were evaluated, according to the recommendations
reported by Hanno et al. (20) and reported in Table 1.
If the biopsy wasn't adequately sized (< 1 mm2-wide), we decided to evaluate the most
reliable parameters, giving a N.V. (Not Valuable) response to the others.
Such parameters were single-blindly studied by two independent pathologists using optic
microscopes (Nikon, mod. Eclipse™ E400 and mod. Eclipse™ CI) and discordant cases were then
discussed jointly.
Immunohistochemical Studies Immunohistochemical reactions with Dako monoclonal antibody
anti-Human Mast-cell Tryptase (Clone AA1; IgG1, Kappa), at 1:4000 dilution, were performed
in order to highlight the mast-cell component of the inflammatory infiltrate, and then to
quantify it. According to the protocol followed at the Laboratory of Immunohistochemistry of
the Pathology Unit the automatic immunostainer Dako Omnis™ was used.
Evaluation of the Immunostainings
The reactions were evaluated using optic microscopes (Nikon, mod. Eclipse™ E400 and mod.
Eclipse™ CI). The following parameters were studied:
- Number of mast-cells/mm2 of mucosa;
- Number of mast-cells/mm2 of submucosa;
- Number of mast-cells/mm2 of the detrusor layer. In order to obtain the highest
accuracy, a single-blind evaluation was performed by two independent pathologists;
discordant or uncertain cases were then discussed jointly.
All patients were evaluated retrospectively using patient files, they were given a score
between 0 to 5 according to the presence of the following criteria (each criteria counting
one point): pain, nocturia, a bladder capacity of 500 mL, glomerulations, or interfascicular
fibrosis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04313972 -
IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone
|
Phase 4 | |
Recruiting |
NCT02868775 -
A Study to Determine the Role of Toll-like Receptor-4 Expression in Patients With Interstitial Cystitis/Bladder Pain Syndrome
|
N/A | |
Not yet recruiting |
NCT01410461 -
Identifying Predictors of Treatment Success in Painful Bladder Syndrome
|
N/A | |
Completed |
NCT01197261 -
OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)
|
Phase 2 | |
Completed |
NCT00150488 -
URACYST® For the Treatment of GAG Deficient Interstitial Cystitis
|
N/A | |
Completed |
NCT00672087 -
Diagnostic Challenges in IC (and Male CPPS)
|
||
Completed |
NCT02232282 -
Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial
|
N/A | |
Completed |
NCT00775281 -
Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC.
|
N/A | |
Completed |
NCT05223244 -
Bladder Capacity as Objective Measure of Intravesical Treatment of Newly Diagnosed IC
|
Phase 4 | |
Completed |
NCT02600715 -
Reduction of Bladder Injection Pain With Belladonna Opiate Suppository
|
Phase 4 | |
Completed |
NCT02457182 -
Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome
|
N/A | |
Withdrawn |
NCT03027076 -
Microbiome of Urologic Chronic Pelvic Pain Syndrome
|
N/A | |
Completed |
NCT00434343 -
Physical Therapy Trial for Pelvic Pain
|
N/A | |
Terminated |
NCT03143920 -
Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder
|
Early Phase 1 | |
Completed |
NCT02411110 -
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
Completed |
NCT00903643 -
Sensory Processing in Subjects With Painful Bladder Syndrome
|
N/A | |
Completed |
NCT00194610 -
Botox as a Treatment for Interstitial Cystitis in Women
|
Phase 4 | |
Recruiting |
NCT06299683 -
Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment
|
N/A | |
Terminated |
NCT04268810 -
Prospective Trial Comparing Intravesical Chondroitin Sulphate 2% and DMSO in the Treatment of PBS/Interstitial Cystitis
|
Phase 4 | |
Completed |
NCT01294878 -
Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 3 |